Search

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

EuroBloodNet aims for better care for patients with rare blood disorders

ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more

Registration

Register for the on-demand recordings

Individual registration
The virtual registration includes:

On-demand access to the recordings of the scientific and educational sessions of the meeting that took place 10-12 November, 2022.

Read more

EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders

EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.

Read more

Good Governance Committee

Current committee members
Wim Fibbe, Netherlands (Chair)
Laurent Degos, France
Jean-Luc Harousseau, France
Cristina Mecucci, Italy
Helen Papadaki, Greece
Irene Roberts, United Kingdom
Pieter Sonneveld, Netherlands
AimThe Good Governance Committee (GGC) is responsible for guarding EHA’s image, position and performance as a non-profit membership organization for the public…

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more